Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclatasvir + sofosbuvir in children with chronic hepatitis C
2017-003338-94Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daclatasvir and sofosbuvir in hepatitis C virus infection, sponsored by Bristol Myers Squibb. Primary endpoint: Daclatasvir pharmacokinetic parameters on Day 10. Started Feb 2018; status: completed.
02
Drugs
daclatasvirsofosbuvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2017-003338-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003338-94.